EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dendrimer-Conjugated Glutamine Antagonist, D-TTM020, Ameliorates Brain Immune Dysregulation and Improves Neurobehavioral Deficits in the Mecp2-Deficient Mouse Model

Preeti Vyas iD, Elizabeth Smith Khoury, Nirnath Sah iD, Anjali Sharma, Javier Allende Labastida iD, Elizabeth L Wilkinson iD, Kathleen Lac, Nerketa N L Damiba, Amanda Fowler, Jinhuan Liu, Ashley Bedner, Pavel Majer und 6 weitere

Cells · 2026

DOI: 10.3390/cells15030272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Preeti Vyas und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD 21287, USA. Hauptthemen laut MEDLINE: Methyl-CpG-Binding Protein 2, Glutamine, Dendrimers, Brain. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health (NIH), United States, Project National Institute for Cancer Research, EU, Targeted therapies for Rett Syndrome.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rett Syndrome (RTT) is a neurodevelopmental disorder characterized by mutations in the MeCP2 gene, predominantly affecting females. Recent work with MeCP2-deficient mouse models showed a significant role in glutamatergic transmission, specifically microglia-produced glutamate and glutaminase upregulation, in RTT pathology. The glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) is a potent glutaminase inhibitor; however, its use is limited due to systemic toxicities arising from its non-specific inhibition of glutamine-utilizing reactions. In this work, we determined whether dendrimer conjugation of a DON analog, TTM020 (or D-TTM020), results in targeted microglial glutaminase inhibition and behavioral changes in Mecp2 KO and heterozygous mice upon systemic administration. D-TTM020 at 1 mg/kg (drug basis) selectively and significantly inhibits glutaminase enzyme activity in the microglia of Mecp2 KO mice. Biweekly systemic treatment with 1 mg/kg of D-TTM020 improved the neurobehavioral phenotype in symptomatic Mecp2 KO and het mice. D-TTM020 also restored long-term retrieval of conditioned fear memory and improved cue responses during fear extinction after 8 weeks of treatment in symptomatic Mecp2 het mice. Our data indicate that selectively targeting glutamine metabolism in dysregulated glia using dendrimers represents a promising strategy that may offer a therapeutic approach for addressing glutamate dysregulation in RTT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methyl-CpG-Binding Protein 2GlutamineDendrimersBrainBehavior, AnimalRett SyndromeDiazooxonorleucineAnimalsMiceDisease Models, AnimalMice, KnockoutGlutaminaseMicrogliaFemaleMice, Inbred C57BL

Stichwörter der Autor:innen

D-TTM020Rett Syndromedendrimerglutaminaseglutaminergic pathwaymicrogliananomedicinenanotherapyneurobehavioral studiestargeted therapy

Substanzen

Methyl-CpG-Binding Protein 2GlutamineDendrimersGlutaminaseMecp2 protein, mouseDiazooxonorleucine

Autor:innen und Institutionen

  • Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD 21287, USA.
  • Center for Nanomedicine, Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
  • Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 160 00 Prague, Czech Republic.
  • Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Department of Neurology, Johns Hopkins University, Baltimore, MD 21218, USA.

ORCID-Profile: Preeti Vyas, Nirnath Sah, Javier Allende Labastida, Elizabeth L Wilkinson, Ajit G Thomas, Rana Rais, Barbara S Slusher, Sujatha Kannan

Förderung

  • National Institutes of Health (NIH), United States
  • Project National Institute for Cancer Research, EU
  • Targeted therapies for Rett Syndrome
  • National Institute for Cancer Research

Zitieren

APA

Vyas, P., Khoury, E. S., Sah, N., Sharma, A., Allende Labastida, J., Wilkinson, E. L., Lac, K., Damiba, N. N. L., Fowler, A., Liu, J., Bedner, A., Majer, P., Tichý, T., Thomas, A. G., Rais, R., Slusher, B. S., Kannan, R. M., & Kannan, S. (2026). Dendrimer-Conjugated Glutamine Antagonist, D-TTM020, Ameliorates Brain Immune Dysregulation and Improves Neurobehavioral Deficits in the Mecp2-Deficient Mouse Model. Cells. https://doi.org/10.3390/cells15030272

Vancouver

Vyas P, Khoury ES, Sah N, Sharma A, Allende Labastida J, Wilkinson EL, et al. Dendrimer-Conjugated Glutamine Antagonist, D-TTM020, Ameliorates Brain Immune Dysregulation and Improves Neurobehavioral Deficits in the Mecp2-Deficient Mouse Model. Cells. 2026. doi:10.3390/cells15030272

BibTeX
@article{Vyas2026,
  author = {Vyas, Preeti and Khoury, Elizabeth Smith and Sah, Nirnath and Sharma, Anjali and Allende Labastida, Javier and Wilkinson, Elizabeth L and Lac, Kathleen and Damiba, Nerketa N L and Fowler, Amanda and Liu, Jinhuan and Bedner, Ashley and Majer, Pavel and Tichý, Tomás and Thomas, Ajit G and Rais, Rana and Slusher, Barbara S and Kannan, Rangaramanujam M and Kannan, Sujatha},
  title = {Dendrimer-Conjugated Glutamine Antagonist, D-TTM020, Ameliorates Brain Immune Dysregulation and Improves Neurobehavioral Deficits in the Mecp2-Deficient Mouse Model},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15030272}
}
Kostenlos starten →